Johnson & Johnson Company News

What you need to know about Johnson & Johnson’s first-quarter 2026 earnings report - Johnson & Johnson

What you need to know about Johnson & Johnson’s first-quarter 2026 earnings report Johnson & Johnson

Farther Finance Advisors LLC Acquires 23,522 Shares of Johnson & Johnson $JNJ - MarketBeat

Farther Finance Advisors LLC Acquires 23,522 Shares of Johnson & Johnson $JNJ MarketBeat

Is Johnson & Johnson (JNJ) Still Attractive After A 53% One Year Share Price Surge - simplywall.st

Is Johnson & Johnson (JNJ) Still Attractive After A 53% One Year Share Price Surge simplywall.st

Morgan Stanley has a bold message for Johnson & Johnson - thestreet.com

Morgan Stanley has a bold message for Johnson & Johnson thestreet.com

From Band-Aids to biotech, Johnson & Johnson became an American icon - USA Today

From Band-Aids to biotech, Johnson & Johnson became an American icon USA Today

What Will Make Johnson & Johnson's Ottava Robot Stand Out? - Medical Device and Diagnostic industry

What Will Make Johnson & Johnson's Ottava Robot Stand Out? Medical Device and Diagnostic industry

J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde - Fierce Pharma

J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde Fierce Pharma

J&J tops first-quarter profit estimates even as Stelara sales plunge - CNBC

J&J tops first-quarter profit estimates even as Stelara sales plunge CNBC

Johnson & Johnson raises guidance for 2026 on strong start to the year - MarketWatch

Johnson & Johnson raises guidance for 2026 on strong start to the year MarketWatch

How J&J plans to hit $100B in revenue this year - Pharma Voice

How J&J plans to hit $100B in revenue this year Pharma Voice

J&J leans on Tremfya, cancer drugs to overcome Stelara losses - BioPharma Dive

J&J leans on Tremfya, cancer drugs to overcome Stelara losses BioPharma Dive

Johnson & Johnson beats Q1 2026 earnings estimates and raises full-year outlook - qz.com

Johnson & Johnson beats Q1 2026 earnings estimates and raises full-year outlook qz.com

J&J’s cardiovascular unit stands out again in Q1 - MedTech Dive

J&J’s cardiovascular unit stands out again in Q1 MedTech Dive

How Johnson & Johnson helped shape America - Asbury Park Press

How Johnson & Johnson helped shape America Asbury Park Press

Coca-Cola vs. Johnson & Johnson: The Safest Dividend on Wall Street Might Surprise You - 24/7 Wall St.

Coca-Cola vs. Johnson & Johnson: The Safest Dividend on Wall Street Might Surprise You 24/7 Wall St.

Earnings call transcript: Johnson & Johnson Q1 2026 earnings beat expectations - Investing.com

Earnings call transcript: Johnson & Johnson Q1 2026 earnings beat expectations Investing.com

Johnson & Johnson $JNJ is Rede Wealth LLC's 4th Largest Position - MarketBeat

Johnson & Johnson $JNJ is Rede Wealth LLC's 4th Largest Position MarketBeat

J&J among Fortune 2026 America’s Most Innovative Companies list - Johnson & Johnson

J&J among Fortune 2026 America’s Most Innovative Companies list Johnson & Johnson

Atwater Malick LLC Trims Holdings in Johnson & Johnson $JNJ - MarketBeat

Atwater Malick LLC Trims Holdings in Johnson & Johnson $JNJ MarketBeat

Wells Fargo & Company Issues Positive Forecast for Johnson & Johnson (NYSE:JNJ) Stock Price - MarketBeat

Wells Fargo & Company Issues Positive Forecast for Johnson & Johnson (NYSE:JNJ) Stock Price MarketBeat

MeiraGTx, spying hope in a failed trial, buys back eye disease gene therapy from J&J - BioSpace

MeiraGTx, spying hope in a failed trial, buys back eye disease gene therapy from J&J BioSpace

Johnson & Johnson (NYSE:JNJ) Stock Price Down 1.7% - Time to Sell? - MarketBeat

Johnson & Johnson (NYSE:JNJ) Stock Price Down 1.7% - Time to Sell? MarketBeat

Johnson & Johnson Reports Strong Q1 Earnings, Raises Its 2026 Guidance - VisionMonday.com

Johnson & Johnson Reports Strong Q1 Earnings, Raises Its 2026 Guidance VisionMonday.com

Why Dow Jones' J&J Is Wavering Despite Its First-Quarter Beat And Raise - Investor's Business Daily

Why Dow Jones' J&J Is Wavering Despite Its First-Quarter Beat And Raise Investor's Business Daily

Leerink Partners Increases Johnson & Johnson (NYSE:JNJ) Price Target to $252.00 - MarketBeat

Leerink Partners Increases Johnson & Johnson (NYSE:JNJ) Price Target to $252.00 MarketBeat

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims - The Economic Times

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims The Economic Times

Dividend Roundup: Johnson & Johnson, Costco, Caterpillar, CVS Health, and more - Seeking Alpha

Dividend Roundup: Johnson & Johnson, Costco, Caterpillar, CVS Health, and more Seeking Alpha

Johnson & Johnson $JNJ Shares Sold by Private Wealth Management Group LLC - MarketBeat

Johnson & Johnson $JNJ Shares Sold by Private Wealth Management Group LLC MarketBeat

Governor Shapiro Secures Over $1 Billion Investment from Johnson & Johnson to Build New Cancer-Fighting Manufacturing Facility in Montgomery County, Creating More Than 500 New Jobs - PA Department of Community & Economic Development (.gov)

Governor Shapiro Secures Over $1 Billion Investment from Johnson & Johnson to Build New Cancer-Fighting Manufacturing Facility in Montgomery County, Creating More Than 500 New Jobs PA Department of Community & Economic Development (.gov)